Seok-Goo Cho

Emailchosgcatholic.ackr

h-index

Research activity per year

Research interests

Development of Cancer Immunotherapy > EBV-CTL in EBV-associated Lymphoma
Adoptive Cell Therapy following Autologous & Allogeneic HSCT
Intentional Induction of Allogeneic Mixed chimerism for Solid Organ Transplantation
Combinatory Cell-Based Immune Modulation with Mesenchymal Stem Cells & Regulatory Cells
Integration of Molecular Imaging in Translational Research

Education

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
The Catholic University of Korea, College of Medicine, Seoul, Korea	M.D.	1988	Medicine
The Catholic Catholic Graduate School of Medicine, Seoul, Korea	M.S.	1992	Internal Medicine
	Ph.D.	1998	Internal Medicine/Hematology

Professional Experience

1988-1995	Received Medical Doctor License (No.35974), Ministry of Health, Korea
1988-1989	Internship and Resident in Kangnam St. Mary Hospital, The Catholic University of Korea College of Medicine
1989-1992	Residency in St. Mary Hospital, The Catholic University of Korea College of Medicine
1992	Received Board Certificate of Internal Medicine (No. 3531), Korea
1992-1995	Served in Korean Army as physician
1995-1996	Fellowship of Internal medicine in St. Mary Hospital, Catholic Blood and Marrow Transplantation Center
1997	Board certified in subspecialty of Hematology, (No 697117) Korea
2001-2003	A scholarship research fellow of a TBRF (Tokyo Biochemical Research Foundation) postdoctoral fellowship program, Department of Molecular therapy, The Institute of Medical Science, The University of Tokyo (IMUST), Japan
1996-2009	Instructor, Assistant Professor, Associate Professor, Department of Hematology, The Catholic University of Korea College of Medicine
2009-2017	Director, Cell Therapy Center, Seoul St. Mary’s Hospital
2013-2017	Director, Catholic Institute of Cell Therapy, The Catholic University of Korea Institute of Biomedical Industry
2014-present	Director, Institute of Translational Research and Molecular Imaging, The Catholic University of Korea
2019-2021	Director, Lymphoma and Cell Therapy Research Center, Yeouido St. Mary’s Hospital
2019-2021	Director, Lymphoma-Myeloma Center, Catholic Hematology Hospital
2019-2021	Director, Department of Internal Medicine, Seoul St. Mary’s Hospital
2019-present	Chief Executive Officer, LucasBio Co., Ltd.
2021-present	President/Director of Industry-Academic Cooperation Foundation
2021-present	Dean for Research Affairs, The Catholic University of Korea

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

External positions

President/Director of Industry-Academic Cooperation Foundation, The Catholic University of Korea

Dean for Research Affairs, The Catholic University of Korea

Chief Executive Officer, LucasBio Co., Ltd.

Director, Institute of Translational Research and Molecular Imaging

Fingerprint

Dive into the research topics where Seok-Goo Cho is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

2 Active
14 Finished

A multi-center, Open, randomized, Phase I/II clinical trial to evaluate the safety and efficacy of combined maintenance of rituximab and cytokine-induced killer cells in elderly high-risk DLBCL(Diffuse Large B-Cell Lymphoma) patients responding to the first R-CHOP treatment
Cho, S.-G. (PI)
1/01/21 → 31/12/25
Project: Research
An investigator’s initiated trial to evaluate the safety of cytokine-induced-killer cells during early transplant period of autologous hematopoietic stem cell transplant recipients
Cho, S.-G. (PI)
1/01/21 → 31/12/25
Project: Research
A clinical study to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell treatment in prolonged SARS-CoV-2 infected patients
Cho, S.-G. (CoI)
1/02/23 → 31/12/24
Project: Research
A phase I study to evaluate the safety of four repeated infusions of bone marrow-derived mesenchymal stem cells for the treatment of steroid-refractory and progressive chronic graft-versus host disease
Cho, S.-G. (PI)
8/11/16 → 31/07/19
Project: Research
TLR5 agonist (KMRC011) for treatment of graft-versus-host disease and enhancement of graft-versus-tumor effect
Cho, S.-G. (PI)
1/11/16 → 31/12/17
Project: Research

261 Article
13 Letter
6 Review article
4 Comment/debate
More

Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia
Ahn, J., Yoon, J. H., Kwag, D., Min, G. J., Park, S. S., Park, S., Lee, S. E., Cho, B. S., Eom, K. S., Kim, Y. J., Kim, H. J., Min, C. K., Cho, S. G. & Lee, S., Oct 2024, In: Bone Marrow Transplantation. 59, 10, p. 1413-1422 10 p.
Research output: Contribution to journal › Article › peer-review
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab
Qing, M., Zhou, T., Perova, T., Abraham, Y., Sweeney, C., Krevvata, M., Zhang, X., Qi, M., Gao, G., Kim, T. M., Yao, M., Cho, S. G., Eom, H. S., Lim, S. T., Yeh, S. P., Kwong, Y. L., Yoon, D. H., Kim, J. S., Kim, W. S. & Zhou, L. & 2 others, Attar, R. & Verona, R. I., May 2024, In: Annals of Hematology. 103, 6, p. 1989-2001 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study
Min, G. J., Rhee, C. K., Kim, T. Y., Jeon, Y. W., Joo Hyun, O., Choi, B. O., Park, G. & Cho, S. G., 1 Jul 2024, In: Acta Haematologica. 147, 4, p. 413-426 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model
Gil, S., Im, K. I., Kim, N., Lee, J., Na, H., Min, G. J. & Cho, S. G., 2024, In: International Journal of Medical Sciences. 21, 9, p. 1649-1660 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1
Park, S., Bang, S. Y., Kwag, D., Lee, J. H., Kim, T. Y., Lee, J., Min, G. J., Park, S. S., Yahng, S. A., Jeon, Y. W., Shin, S. H., Yoon, J. H., Lee, S. E., Cho, B. S., Eom, K. S., Kim, Y. J., Lee, S., Min, C. K., Cho, S. G. & Lee, J. W. & 1 others, Kim, H. J., Jun 2024, In: Bone Marrow Transplantation. 59, 6, p. 813-823 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations

New Findings in Acute Myeloid Leukemia Described from Catholic University of Korea (A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid ...)
Kim, Y. J., Lee, S., Eom, K. S., Park, S., Lee, S. E., Kim, H. J., Cho, B. S., Cho, S. G., Min, G. J. & Lee, E. K.
24/03/23
1 item of Media coverage
Press/Media
Catholic University of Korea Details Findings in Chemotherapy (Geriatric Assessment Predicts Nonfatal Toxicities and Survival for Intensively Treated Older Adults With Aml)
Kim, Y. J., Lee, S., Yahng, S. A., Eom, K. S., Park, S., Lee, S. E., Cho, B. S., Cho, S. G., Min, G. J., Lee, E. K. & Woo, Y. S.
10/03/23
1 item of Media coverage
Press/Media
Researchers from Catholic University of Korea Report on Findings in Lymphoma (Diagnosis, Treatment, and Prognosis of Primary Intraocular Lymphoma: Single-center Real-world Clinical Experience)
Choi, B. O., Park, Y. H., Cho, S. G., Min, G. J. & Woo, Y. S.
6/03/23
1 item of Media coverage
Press/Media
Data on Graft-Versus-Host Disease Detailed by Researchers at Catholic University of Korea (BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis)
Cho, S. G. & Jeon, Y. W.
21/12/22
1 item of Media coverage
Press/Media
US Patent Issued to CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION on Oct. 6 for "Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient" (South
Cho, M. L. & Cho, S. G.
6/10/20
1 item of Media coverage
Press/Media

Seok-Goo Cho

Personal profile

Research interests

Education

Professional Experience

Expertise related to UN Sustainable Development Goals

External positions

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

A multi-center, Open, randomized, Phase I/II clinical trial to evaluate the safety and efficacy of combined maintenance of rituximab and cytokine-induced killer cells in elderly high-risk DLBCL(Diffuse Large B-Cell Lymphoma) patients responding to the first R-CHOP treatment

An investigator’s initiated trial to evaluate the safety of cytokine-induced-killer cells during early transplant period of autologous hematopoietic stem cell transplant recipients

A clinical study to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell treatment in prolonged SARS-CoV-2 infected patients

A phase I study to evaluate the safety of four repeated infusions of bone marrow-derived mesenchymal stem cells for the treatment of steroid-refractory and progressive chronic graft-versus host disease

TLR5 agonist (KMRC011) for treatment of graft-versus-host disease and enhancement of graft-versus-tumor effect

Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia

Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study

Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model

Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1

New Findings in Acute Myeloid Leukemia Described from Catholic University of Korea (A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid ...)

Catholic University of Korea Details Findings in Chemotherapy (Geriatric Assessment Predicts Nonfatal Toxicities and Survival for Intensively Treated Older Adults With Aml)

Researchers from Catholic University of Korea Report on Findings in Lymphoma (Diagnosis, Treatment, and Prognosis of Primary Intraocular Lymphoma: Single-center Real-world Clinical Experience)

Data on Graft-Versus-Host Disease Detailed by Researchers at Catholic University of Korea (BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis)

US Patent Issued to CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION on Oct. 6 for "Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient" (South

Seok-Goo Cho

Personal profile

Research interests

Education

Professional Experience

Expertise related to UN Sustainable Development Goals

External positions

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output

Press/Media